REGISTRY OF COMPLETE RESPONSES TO SUNITINIB IN SPANISH PATIENTS WITH METASTATIC RENAL CELL CARCINOMA

Back to Search
Print
Bookmark Trial

NCT03916458

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Hospital Universitario Central de Asturias
Oviedo, Asturias, 33011, Spain
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Renal Cell Carcinoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Patients who are 18 year-old or over who have been treated for metastatic renal cell carcinoma with sunitinib as first-line treatment (treatment with prior cytokine therapy is accepted) between 2007 and 30 September 2018 and who have obtained as a best treatment response the total remission of the disease in the opinion of the doctor in charge from a clinical, radiological and/or macroscopic point of view. This response must have been reached through two possible strategies:

A) Systemic treatment with sunitinib alone. B) Treatment with sunitinib and subsequent local treatment for one or more residual lesions that have not responded to the drug (traditional surgery, radiotherapy, SBRT (Stereotactic Body Radiation Therapy)).

2. The duration of CR must have been confirmed with at least 2 consecutive imaging tests, without having a limit in the duration of this response. Although the patient had progressed subsequently, he/she may be included in this registry.

3. Patients from any risk group

4. Tumours of any histology

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. Patients treated with another drug other than Sunitinib.


2. Patients with no radiology reports proving CR.


3. Patients with no record of the dose and regimen received with Sunitinib.


4. Patients who achieved complete remission after 30 September 2018.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Renal Cell CarcinomaAxitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer NCT00835978
  1. Antioch, California
  2. Bakersfield, California
  3. Pleasant Hill, California
  4. Pleasant Hill, California
  5. Pleasant Hill, California
  6. San Leandro, California
  7. Tampa, Florida
  8. Indianapolis, Indiana
  9. Indianapolis, Indiana
  10. Indianapolis, Indiana
  11. Baltimore, Maryland
  12. Baltimore, Maryland
  13. Baltimore, Maryland
  14. Boston, Massachusetts
  15. Boston, Massachusetts
  16. Grand Rapids, Michigan
  17. Saint Louis, Missouri
  18. Saint Louis, Missouri
  19. Omaha, Nebraska
  20. Omaha, Nebraska
  21. Las Vegas, Nevada
  22. Cincinnati, Ohio
  23. Cincinnati, Ohio
  24. Cleveland, Ohio
  25. Columbus, Ohio
  26. Columbus, Ohio
  27. West Chester, Ohio
  28. Portland, Oregon
  29. Dallas, Texas
  30. Houston, Texas
  31. Seattle, Washington
  32. Brno, CZE
  33. Olomouc,
  34. Praha 8,
  35. Usti nad Labem,
  36. Duesseldorf,
  37. Frankfurt,
  38. Hannover,
  39. Tuebingen,
  40. Weiden,
  41. Nagoya, Aichi
  42. Sapporo, Hokkaido
  43. Sapporo, Hokkaido
  44. Kobe, Hyogo
  45. Osakasayama, Osaka
  46. Hamamatsu-City, Shizuoka
  47. Chuo-ku, Tokyo
  48. Koto-ku, Tokyo
  49. Shinjuku-ku, Tokyo
  50. Akita,
  51. Chiba,
  52. Fukuoka,
  53. Nagasaki,
  54. Tokushima,
  55. Yamagata,
  56. Obninsk, Kaluga Region
  57. Poselok Kuzmolovskiy, Vsevolozhskiy Region, Leningradskaya Oblast
  58. Moscow,
  59. Moscow,
  60. Saint-Petersburg,
  61. Saint-Petersburg,
  62. Samara,
  63. Madrid,
  64. Madrid,
  65. Madrid,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Renal Cell CarcinomaTreatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma NCT00130897
  1. Scottsdale, Arizona
  2. San Francisco, California
  3. San Francisco, California
  4. Aurora, Colorado
  5. Norwalk, Connecticut
  6. Miami, Florida
  7. Ocala, Florida
  8. Tampa, Florida
  9. Atlanta, Georgia
  10. Maywood, Illinois
  11. Indianapolis, Indiana
  12. Council Bluffs, Iowa
  13. Covington, Louisiana
  14. Gretna, Louisiana
  15. Marrero, Louisiana
  16. Metairie, Louisiana
  17. Metairie, Louisiana
  18. New Orleans, Louisiana
  19. Baltimore, Maryland
  20. Boston, Massachusetts
  21. Boston, Massachusetts
  22. Boston, Massachusetts
  23. Detroit, Michigan
  24. Minneapolis, Minnesota
  25. Southaven, Mississippi
  26. Tupelo, Mississippi
  27. Columbia, Missouri
  28. Columbia, Missouri
  29. Omaha, Nebraska
  30. Bronx, New York
  31. New York, New York
  32. New York, New York
  33. Durham, North Carolina
  34. Cleveland, Ohio
  35. Norman, Oklahoma
  36. Oklahoma City, Oklahoma
  37. Oklahoma City, Oklahoma
  38. Oklahoma City, Oklahoma
  39. Oklahoma City, Oklahoma
  40. Tulsa, Oklahoma
  41. Tulsa, Oklahoma
  42. Portland, Oregon
  43. Portland, Oregon
  44. Hershey, Pennsylvania
  45. Memphis, Tennessee
  46. Memphis, Tennessee
  47. Dallas, Texas
  48. Salt Lake City, Utah
  49. Seattle, Washington
  50. Seattle, Washington
  51. Seattle, Washington
  52. Seattle, Washington
  53. Madison, Wisconsin
  54. Buenos Aires,
  55. Buenos Aires,
  56. Buenos Aires,
  57. Randwick, New South Wales
  58. St Leonards, New South Wales
  59. Westmead, New South Wales
  60. South Brisbane, Queensland
  61. Elizabeth Vale, South Australia
  62. Woodville South, South Australia
  63. East Melbourne, Victoria
  64. Heidelburg, Victoria
  65. Perth, Western Australia
  66. Innsbruck,
  67. Wien,
  68. Bruxelles,
  69. Bruxelles,
  70. Gent,
  71. Leuven,
  72. Liege,
  73. Wilrijk,
  74. Sarajevo,
  75. Salvador, BA
  76. Belo Horizonte, MG
  77. Porto Alegre, Rio Grande do Sul
  78. Rio de Janeiro, RJ
  79. Rio de Janeiro, RJ
  80. Porto Alegre, RS
  81. Jau, SP
  82. Jaú, SP
  83. Jaú, SP
  84. São Paulo, SP
  85. São Paulo, SP
  86. São Paulo, SP
  87. Sofia,
  88. Sofia,
  89. Calgary, Alberta
  90. Edmonton, Alberta
  91. Kelowna, British Columbia
  92. Vancouver, British Columbia
  93. Victoria, British Columbia
  94. Winnipeg, Manitoba
  95. Winnnipeg, Manitoba
  96. St. John's, Newfoundland and Labrador
  97. Halifax, Nova Scotia
  98. Halifax, Nova Scotia
  99. London, Ontario
  100. Toronto, Ontario
  101. Toronto, Ontario
  102. Montreal, Quebec
  103. Montreal, Quebec
  104. Quebec,
  105. Santiago, RM
  106. Bogotá, Cundinamarca
  107. Cali,
  108. Rijeka,
  109. Split,
  110. Brno,
  111. Hradec Kralove,
  112. Praha 5,
  113. Praha 8,
  114. Guayaquil, Guayas
  115. Quito, Pichincha
  116. Cairo,
  117. Giza,
  118. Turku,
  119. Lyon, Cedex 08
  120. Saint Herblain, Cedex
  121. Strasbourg, Cedex
  122. Bordeaux,
  123. Clermont Ferand,
  124. Marseille Cedex 9,
  125. Marseille,
  126. Montpellier,
  127. Paris Cedex 13,
  128. Paris,
  129. Reims,
  130. Rennes,
  131. Tours,
  132. Vandoeuvre les Nancy,
  133. Aachen,
  134. Berlin,
  135. Dresden,
  136. Essen,
  137. Frankfurt,
  138. Freiburg,
  139. Hamburg,
  140. Hannover,
  141. Homburg/Saar,
  142. Jena,
  143. Kassel,
  144. Muenchen,
  145. Nuernberg,
  146. Rostock,
  147. Ulm,
  148. Athens, Attiki
  149. Athens,
  150. Patras,
  151. Thessaloniki,
  152. Hong Hong,
  153. Budapest,
  154. New Delhi, Delhi
  155. Pune, Maharashtra
  156. Parel, Mumbai
  157. Jaipur, Rajasthan
  158. New Delhi,
  159. Dublin 24,
  160. Dublin,
  161. Jerusalem,
  162. Tel Hashomer,
  163. Bergamo,
  164. Brescia,
  165. Cattolica (RN),
  166. Cuneo,
  167. Legnago, VR,
  168. Modena,
  169. Napoli,
  170. Padova,
  171. Parma,
  172. Pavia,
  173. Perugia,
  174. Pordenone,
  175. Rimini,
  176. Roma,
  177. Roma,
  178. Roma,
  179. Torino,
  180. Seoul,
  181. Seoul,
  182. Beirut,
  183. Petaling Jaya, Selangor
  184. Kuala Lumpur,
  185. Mexico, DF
  186. Mexico, DF
  187. Toluca, Estado de Mexico
  188. Guadalajara, Jalisco
  189. Merida, Yucatan
  190. Chihuahua,
  191. Puebla,
  192. Groningen, GR
  193. Amsterdam, NH
  194. Amsterdam,
  195. Rotterdam,
  196. Oslo,
  197. Ciudad de Panama,
  198. Panama,
  199. Lima,
  200. Lima,
  201. Quezon City,
  202. Quezon City,
  203. Gdansk,
  204. Lodz,
  205. Poznan,
  206. Warszawa,
  207. Wroclaw,
  208. Lisboa,
  209. Porto,
  210. Bucuresti,
  211. Cluj-Napoca,
  212. Obninsk, Kaluga region
  213. Chelyabinsk,
  214. Moscow,
  215. Belgrade,
  216. Singapore,
  217. Bratislava,
  218. Zilina,
  219. Ljubljana,
  220. Oviedo, Asturias
  221. L'hospitalet Del Llobregat, Barcelona
  222. Pamplona, Navarra
  223. Baracaldo, Vizcaya
  224. Barcelona,
  225. Barcelona,
  226. La Coruña,
  227. Madrid,
  228. Madrid,
  229. Madrid,
  230. Salamanca,
  231. Sevilla,
  232. Valencia,
  233. Göteborg,
  234. Lund,
  235. Stockholm,
  236. Umeå,
  237. Basel,
  238. Bellinzona,
  239. Bern,
  240. Biel,
  241. CH-4058 Basel,
  242. CH-4101 Bruderholz,
  243. CH-4410 Liesthal,
  244. Chur,
  245. Genève 14,
  246. Taipei,
  247. Taipei,
  248. Taoyun,
  249. Bangkok,
  250. Bangkok,
  251. Istanbul, Capa
  252. Istanbul, Cerrahpasa
  253. Whitchurch, Cardiff
  254. London, Se1 9rt
  255. Sutton, Surrey
  256. Leeds, West Yorkshire
  257. Belfast,
  258. Birmingham,
  259. Birmingham,
  260. Bristol,
  261. Cottingham,
  262. Edinburgh,
  263. Guildford,
  264. London,
  265. London,
  266. London,
  267. Manchester,
  268. Northwood,
  269. Nottingham,
  270. Sheffield,
  271. Southampton,
  272. Swansea,
  273. Caracas, Distrito Capital
  274. Caracas, Estado Miranda
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Renal Cell CarcinomaSUTENT® In The First Line Treatment Of Renal Cell Carcinoma NCT00460798
ALL GENDERS
0+
years
MULTIPLE SITES
Renal Cell CarcinomaA Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma. NCT00077974
  1. Duarte, California
  2. Pasadena, California
  3. San Francisco, California
  4. Boston, Massachusetts
  5. Boston, Massachusetts
  6. Boston, Massachusetts
  7. Ann Arbor, Michigan
  8. Rochester, Minnesota
  9. New York, New York
  10. New York, New York
  11. Durham, North Carolina
  12. Cleveland, Ohio
  13. Portland, Oregon
  14. Philadelphia, Pennsylvania
  15. Madison, Wisconsin
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title REGISTRY OF COMPLETE RESPONSES TO SUNITINIB IN SPANISH PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Official Title REGISTRY OF COMPLETE RESPONSES TO SUNITINIB IN SPANISH PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (ATILA STUDY)
Brief Summary

Observational, retrospective, multicentre study in spanish patients with metastatic Renal Cell Carcinoma (mRCC) treated with sunitinib as a first-line treatment (treatment with previous cytokine therapy is accepted) according to clinical practice who obtained a complete response (CR) to treatment in one of these 2 situations:

  1. Complete response (CR) obtained exclusively with first-line sunitinib treatment (sunitinib CR).
  2. Response obtained after a period of time on treatment with sunitinib in which local treatment was also performed (surgery of the residual metastasis/metastases, radiofrequency ablation or radiotherapy) to achieve the total macroscopic disappearance of the disease, according to the opinion of the physician responsible for the patient (CR + local treatment).
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Other
Time Perspective: Retrospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population The patient population eligible for this study includes any patient with advanced or metastatic renal cell cancer who has been treated with Sunitinib and has achieved CR of the tumour and its metastases at any time during treatment and according to the usual assessment criteria in daily clinical practice, whether it was obtained with sunitinib alone or if a local treatment was needed to eradicate all the lesions: (surgery of the residual metastases, radiofrequency ablation or radiotherapy)
Condition Carcinoma, Renal Cell
Intervention Not Provided
Study Groups/Cohorts Subjects with reported metastatic renal cell carcinoma
The subjects have been treatment with sunitinib and they reached complete remission
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: April 27, 2020)		40
Original Estimated Enrollment
 (submitted: April 12, 2019)		90
Estimated Study Completion Date September 30, 2020
Estimated Primary Completion Date September 30, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  1. Patients who are 18 year-old or over who have been treated for metastatic renal cell carcinoma with sunitinib as first-line treatment (treatment with prior cytokine therapy is accepted) between 2007 and 30 September 2018 and who have obtained as a best treatment response the total remission of the disease in the opinion of the doctor in charge from a clinical, radiological and/or macroscopic point of view. This response must have been reached through two possible strategies:

    A) Systemic treatment with sunitinib alone. B) Treatment with sunitinib and subsequent local treatment for one or more residual lesions that have not responded to the drug (traditional surgery, radiotherapy, SBRT (Stereotactic Body Radiation Therapy)).

  2. The duration of CR must have been confirmed with at least 2 consecutive imaging tests, without having a limit in the duration of this response. Although the patient had progressed subsequently, he/she may be included in this registry.
  3. Patients from any risk group
  4. Tumours of any histology

Exclusion Criteria:

  1. Patients treated with another drug other than Sunitinib.
  2. Patients with no radiology reports proving CR.
  3. Patients with no record of the dose and regimen received with Sunitinib.
  4. Patients who achieved complete remission after 30 September 2018.
Sex/Gender
Sexes Eligible for Study:All
Ages Child, Adult, Older Adult
Accepts Healthy Volunteers No
Contacts
Contact: Pfizer CT.gov Call Center1-800-718-1021[email protected]
Listed Location Countries Spain
Removed Location Countries  
 
Administrative Information
NCT Number NCT03916458
Other Study ID Numbers A6181227
ATILA ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement
Plan to Share IPD:No
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date April 2020